Targets › PRPF31
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2028.
Involved in pre-mRNA splicing as component of the spliceosome. Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome. (UniProt, Q8WWY3)
Open in Phaseline: the race on PRPF31, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PYC Therapeutics | VP-001 Oligonucleotide-peptide conjugate targeting PRPF31 mutation | PRPF31 | Phase 1 | Retinitis Pigmentosa 11 | Mar 2028 |
Retinitis Pigmentosa 11 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.